TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 38202070

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 79

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 79
Study: 38203214

Group type: EXPERIMENTAL
Intervention: Single-agent regorafenib
Number of subjects: 0
Study: 38203593

Group type: EXPERIMENTAL
Intervention: AAT treatment
Number of subjects: 53
Study: 38204184

Group type: EXPERIMENTAL
Intervention: High-Intensity Training (HIT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional Training
Number of subjects: 0
Study: 38204364

Group type: EXPERIMENTAL
Intervention: Oral tramadol/dexketoprofen (TRAM/DKP)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Intravenous paracetamol + tramadol (PARA+TRAM)
Number of subjects: 323
Study: 38204489

Group type: EXPERIMENTAL
Intervention: Cabozantinib plus atezolizumab
Number of subjects: 61
Study: 38204488

Group type: EXPERIMENTAL
Intervention: Donor-derived anti-CD19 CAR T cells (GC007g)
Number of subjects: 12
Study: 38204600

Group type: EXPERIMENTAL
Intervention: Fluid-filled wire (Wirecath)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional pressure wire (PressureWire X)
Number of subjects: 45
Study: 38204726

Group type: EXPERIMENTAL
Intervention: mGEARS score
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TBS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mGEARS and TBS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: mGEARS
Number of subjects: 0
Study: 38204866

Group type: EXPERIMENTAL
Intervention: Circuit training combining strength (50%-80% 1RM) and endurance (50%-75% HRR) exercise, 33 minutes, three times per week for 12 weeks
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control non-training group (NT)
Number of subjects: 27
Study: 38204945

Group type: EXPERIMENTAL
Intervention: Follicular-phase stimulation (FPS)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Luteal-phase stimulation (LPS)
Number of subjects: 41
Study: 38204957

Group type: EXPERIMENTAL
Intervention: Follicular phase length (FPL) quintiles (q1: ≤11 days, q2: 12 days, q3: 13 days, q4: 14-15 days, q5: ≥16 days)
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate or letrozole
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: Gonadotropins
Number of subjects: 869

Group type: EXPERIMENTAL
Intervention: All treatment groups combined
Number of subjects: 869
Study: 38205016

Group type: EXPERIMENTAL
Intervention: Cancer-associated thrombosis management over time
Number of subjects: 17271

Group type: EXPERIMENTAL
Intervention: Symptomatic VTE recurrences
Number of subjects: 17271

Group type: EXPERIMENTAL
Intervention: Major bleeding
Number of subjects: 17271

Group type: EXPERIMENTAL
Intervention: Death within 30 days after incident VTE
Number of subjects: 17271
Study: 38205035

Group type: EXPERIMENTAL
Intervention: MTC online program during the 8-week period
Number of subjects: 200

Group type: COMPARATOR
Intervention: Waitlist control group receiving the MTC program after an 8-week wait
Number of subjects: 200
Study: 38205442

Group type: EXPERIMENTAL
Intervention: Intrathecal delivery of a bicistronic AAV9 vector expressing β-hexosaminidase A
Number of subjects: 1

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1
Study: 38205507

Group type: EXPERIMENTAL
Intervention: Rituximab plus cyclophosphamide and dexamethasone
Number of subjects: 0
Study: 38205654

Group type: EXPERIMENTAL
Intervention: High noncalcified plaque (NCP) volume
Number of subjects: 454

Group type: COMPARATOR
Intervention: Low noncalcified plaque (NCP) volume
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: High NCP volume
Number of subjects: 454
Study: 38205656

Group type: EXPERIMENTAL
Intervention: Alirocumab 150 mg subcutaneously every 14 days in addition to high-intensity statin therapy
Number of subjects: 104
Study: 38205679

Group type: EXPERIMENTAL
Intervention: Intra-articular injection of allogeneic adipose-derived mesenchymal stem cells (ADSCs) GXCPC1
Number of subjects: 11
Study: 38205822

Group type: EXPERIMENTAL
Intervention: Remimazolam with flumazenil
Number of subjects: 0

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 0
Study: 38205865

Group type: EXPERIMENTAL
Intervention: Low educational level
Number of subjects: 2295

Group type: EXPERIMENTAL
Intervention: Medium educational level
Number of subjects: 2295

Group type: COMPARATOR
Intervention: High educational level
Number of subjects: 2295

Group type: EXPERIMENTAL
Intervention: All-cause death
Number of subjects: 2295

Group type: EXPERIMENTAL
Intervention: Ischemic stroke (IS)
Number of subjects: 2295

Group type: EXPERIMENTAL
Intervention: Intracerebral hemorrhage (ICH)
Number of subjects: 2295
Study: 38206145

Group type: EXPERIMENTAL
Intervention: Clascoterone cream 1%
Number of subjects: 1421
Study: 38206151

Group type: EXPERIMENTAL
Intervention: PLLA-SCA injections (150 mg; 8 mL reconstitution in sterile water for injection) + 1 mL lidocaine hydrochloride (2%)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PLLA-SCA injections
Number of subjects: 0
Study: 38206187

Group type: EXPERIMENTAL
Intervention: Doravirine (biological cutoff 3.0)
Number of subjects: 2705

Group type: EXPERIMENTAL
Intervention: V106I
Number of subjects: 2705

Group type: EXPERIMENTAL
Intervention: Subtype F1
Number of subjects: 2705
Study: 38206455

Group type: EXPERIMENTAL
Intervention: Current moderate exacerbation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Current severe exacerbation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous moderate exacerbation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Previous severe exacerbation
Number of subjects: 0
Study: 38206518

Group type: EXPERIMENTAL
Intervention: Biosimilars (TNF inhibitors) - adalimumab (ADA), etanercept (ETA), infliximab (IFX)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Biosimilars (TNF inhibitors)
Number of subjects: 47
Study: 38206544

Group type: EXPERIMENTAL
Intervention: Umbilical cord mesenchymal stem cells transplantation (UMSCT)
Number of subjects: 41
Study: 38206548

Group type: EXPERIMENTAL
Intervention: Lock to Live (L2L) decision aid
Number of subjects: 21131

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 21131
Study: 38206614

Group type: EXPERIMENTAL
Intervention: Low-dose cohort (4 Gy × 10 fractions + 25 Gy SABR boost, 5 Gy × 5 fractions)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Intermediate-dose cohort (4 Gy × 10 fractions + 30 Gy SABR boost, 6 Gy × 5 fractions)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: High-dose cohort (4 Gy × 10 fractions + 35 Gy SABR boost, 7 Gy × 5 fractions)
Number of subjects: 28
Study: 38206628

Group type: EXPERIMENTAL
Intervention: Direct Lateral Approach (DLA)
Number of subjects: 843

Group type: COMPARATOR
Intervention: Posterolateral Approach (PLA)
Number of subjects: 843
Study: 38206631

Group type: EXPERIMENTAL
Intervention: Mirtazapine 15 mg for 2 weeks followed by 30 mg until week 8
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study: 38206635

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA ≤200 U
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 201-400 U
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 401-600 U
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA 601-800 U
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA ≥801 U
Number of subjects: 730

Group type: EXPERIMENTAL
Intervention: onabotulinumtoxinA
Number of subjects: 730
Study: 38206678

Group type: EXPERIMENTAL
Intervention: Crisaborole
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38206766

Group type: EXPERIMENTAL
Intervention: IL-4 treatment
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: EOS conditioned media
Number of subjects: 15

Group type: COMPARATOR
Intervention: Obesity (n = 15)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Lean subjects (n = 15)
Number of subjects: 15
Study: 38206830

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120 mg plus Temozolomide (TMZ)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Lanreotide Autogel 120 mg maintenance
Number of subjects: 57

Group type: COMPARATOR
Intervention: Observation only (Control)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Combination therapy (LAN plus TMZ)
Number of subjects: 57
Study: 38206849

Group type: EXPERIMENTAL
Intervention: Personal training program
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Home-based program
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Overall exercise intervention
Number of subjects: 44
Study: 38206930

Group type: EXPERIMENTAL
Intervention: Varenicline (0.5‒2 mg) and Bupropion SR (150‒300 mg)
Number of subjects: 380

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study: 38207119

Group type: EXPERIMENTAL
Intervention: Haploidentical NK cells plus IL-2
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Haploidentical NK cells plus N-803
Number of subjects: 6
Study: 38207172

Group type: EXPERIMENTAL
Intervention: PAVS and best practice advisory integrated into EHR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Best practice advisory
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Remote patient monitoring via Fitbit
Number of subjects: 0
Study: 38207195

Group type: EXPERIMENTAL
Intervention: Big-step instruction
Number of subjects: 45

Group type: COMPARATOR
Intervention: Heel strike instruction
Number of subjects: 45
Study: 38207208

Group type: EXPERIMENTAL
Intervention: mini-hyper-CVD plus venetoclax (200 mg or 400 mg daily)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: mini-hyper-CVD plus venetoclax
Number of subjects: 22
Study: 38207246

Group type: EXPERIMENTAL
Intervention: Usual care with proactive symptom assessment (peer volunteer weekly phone calls)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 60
Study: 38207282

Group type: EXPERIMENTAL
Intervention: Gut microbiome analysis of elite athletes with SCI
Number of subjects: 11
Study: 38211393

Group type: EXPERIMENTAL
Intervention: Neratinib 240 mg/day
Number of subjects: 22
Study: 38211601

Group type: EXPERIMENTAL
Intervention: Oral linezolid (600 mg once per day for 5 days)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Intramuscular benzathine penicillin G (single dose of 2.4 million international units)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 59
Study: 38211604

Group type: EXPERIMENTAL
Intervention: Linaclotide 72 μg once daily for 12 weeks
Number of subjects: 330

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 330
Study: 38211606

Group type: EXPERIMENTAL
Intervention: Subtyping-based therapy (nab-paclitaxel 100 mg/m2 in 28-day cycles)
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group (standard treatment)
Number of subjects: 139

Group type: EXPERIMENTAL
Intervention: Subtyping-based therapy
Number of subjects: 139

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 139
Study: 38211660

Group type: EXPERIMENTAL
Intervention: Dalbavancin
Number of subjects: 97
Study: 38211725

Group type: EXPERIMENTAL
Intervention: CoCM plus Written Exposure Therapy (CoCM+WET)
Number of subjects: 720

Group type: COMPARATOR
Intervention: CoCM only
Number of subjects: 720

Group type: EXPERIMENTAL
Intervention: CoCM+WET
Number of subjects: 720
Study: 38211747

Group type: EXPERIMENTAL
Intervention: Meru Health Program (MHP), 12 weeks duration
Number of subjects: 100

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 100
Study: 38211934

Group type: EXPERIMENTAL
Intervention: Endovascular, transcatheter, right-sided greater splanchnic nerve ablation (SAVM)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham control
Number of subjects: 90
Study: 38212048

Group type: EXPERIMENTAL
Intervention: HoloLens-assisted thoracic epidural technique
Number of subjects: 83

Group type: COMPARATOR
Intervention: Traditional thoracic epidural technique
Number of subjects: 83
Study: 38212068

Group type: EXPERIMENTAL
Intervention: Selective Internal Radiation Therapy (SIRT)
Number of subjects: 0
Study: 38212105

Group type: EXPERIMENTAL
Intervention: Polyethylene bag placed before cord clamping (BEFORE)
Number of subjects: 198

Group type: COMPARATOR
Intervention: Polyethylene bag placed after cord clamping (AFTER)
Number of subjects: 198
Study: 38212104

Group type: EXPERIMENTAL
Intervention: CC+SI
Number of subjects: 218

Group type: COMPARATOR
Intervention: 3:1 C:V
Number of subjects: 218
Study: 38212127

Group type: EXPERIMENTAL
Intervention: Intravenous administration of low-dose nivolumab (10 mg, every 2 weeks) plus intratumoral administration of 10 mg ipilimumab and 50 µg AS01
Number of subjects: 8
Study: 38212160

Group type: EXPERIMENTAL
Intervention: Customized 2-wk controlled diet designed to emulate their usual diet
Number of subjects: 153
Study: 38212183

Group type: EXPERIMENTAL
Intervention: Opioid use at M12
Number of subjects: 2326

Group type: EXPERIMENTAL
Intervention: Opioid use at M6
Number of subjects: 2326

Group type: EXPERIMENTAL
Intervention: New opioid users
Number of subjects: 2326

Group type: EXPERIMENTAL
Intervention: Pain and interference reported by M12 opioid users
Number of subjects: 2326

Group type: EXPERIMENTAL
Intervention: Preoperative opioid use
Number of subjects: 2326
Study: 38212206

Group type: EXPERIMENTAL
Intervention: Real-world clinical practice (RWCP) therapy
Number of subjects: 24
Study: 38212245

Group type: EXPERIMENTAL
Intervention: Obesity (BMI of ≥30 kg/m2)
Number of subjects: 2628

Group type: EXPERIMENTAL
Intervention: High physical activity (≥73.5 MET-hours per week)
Number of subjects: 2628

Group type: EXPERIMENTAL
Intervention: Heavy smoking (>30 pack-years)
Number of subjects: 2628

Group type: EXPERIMENTAL
Intervention: Short sleep (<6 hours per day)
Number of subjects: 2628
Study: 38212308

Group type: EXPERIMENTAL
Intervention: Autonomous artificial intelligence diabetic eye exam at the point of care
Number of subjects: 164

Group type: COMPARATOR
Intervention: Scripted eye care provider referral and education (Control)
Number of subjects: 164
Study: 38212321

Group type: EXPERIMENTAL
Intervention: DHES0815A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher doses of DHES0815A
Number of subjects: 0
Study: 38212582

Group type: EXPERIMENTAL
Intervention: Semen BPA (sBPA) levels
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: High semen BPA (sBPA) levels
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Blood BPA (bBPA) levels
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Elevated blood BPA (bBPA) levels
Number of subjects: 75
Study: 38212607

Group type: EXPERIMENTAL
Intervention: DLS-assisted junior ophthalmologist group (test group)
Number of subjects: 748

Group type: COMPARATOR
Intervention: Junior ophthalmologist group (control group)
Number of subjects: 748

Group type: EXPERIMENTAL
Intervention: DLS group
Number of subjects: 748
Study: 38212696

Group type: EXPERIMENTAL
Intervention: Paternal anxiety (measured by GAD-7)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maternal depression (measured by EPDS)
Number of subjects: 0
Study: 38212769

Group type: EXPERIMENTAL
Intervention: DNTGF-βR armored CAR-T cell therapy
Number of subjects: 0
Study: 38212804

Group type: EXPERIMENTAL
Intervention: Sage intervention (12-session manualized intervention)
Number of subjects: 5
Study: 38212815

Group type: EXPERIMENTAL
Intervention: Cognitive training with anodal tDCS (1-mA, 20 min)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Cognitive training with sham stimulation
Number of subjects: 46
Study: 38212823

Group type: EXPERIMENTAL
Intervention: Buteyko breathing technique (BBT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual therapy (UT) without BBT
Number of subjects: 30
Study: 38212837

Group type: EXPERIMENTAL
Intervention: Machine learning (ML) model called IDoser for FSH dosing
Number of subjects: 236

Group type: COMPARATOR
Intervention: Standard practice FSH dosing determined by clinician
Number of subjects: 236
Study: 38212847

Group type: EXPERIMENTAL
Intervention: Daily yogurt consumption (5 oz) for 8 weeks
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no yogurt consumption)
Number of subjects: 20
Study: 38212851

Group type: EXPERIMENTAL
Intervention: Multidimensional individually tailored intervention including Norwegian Psychomotor Physiotherapy (NPMP), cognitive behavioural therapy, and a rehabilitation plan
Number of subjects: 18
Study: 38212850

Group type: EXPERIMENTAL
Intervention: Insulin resistance-related features (IR)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Higher triglyceride (TG) and lower estimated insulin sensitivity (eIS)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Estimated insulin sensitivity (eIS)
Number of subjects: 117
Study: 38212853

Group type: EXPERIMENTAL
Intervention: Cognitive bias modification training (CBMT) - 4-week, 8-session, tablet-delivered intervention
Number of subjects: 49

Group type: COMPARATOR
Intervention: Sham attention control group
Number of subjects: 49
Study: 38212888

Group type: EXPERIMENTAL
Intervention: Barbed suture
Number of subjects: 72

Group type: COMPARATOR
Intervention: Nonbarbed suture
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Both suture types
Number of subjects: 72
Study: 38213401

Group type: EXPERIMENTAL
Intervention: Home-based telerehabilitation (tele-physical/occupational therapy)
Number of subjects: 15
Study: 38213637

Group type: EXPERIMENTAL
Intervention: Dolutegravir-lamivudine (DTG/3TC)
Number of subjects: 741

Group type: COMPARATOR
Intervention: Tenofovir alafenamide-based regimens (TBR)
Number of subjects: 741

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 741
Study: 38214149

Group type: EXPERIMENTAL
Intervention: Brigimadlin (BI 907828)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38214170

Group type: EXPERIMENTAL
Intervention: Metal nanoparticles
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38214239

Group type: EXPERIMENTAL
Intervention: Aspirin use ≤7 days of index stroke
Number of subjects: 1423

Group type: COMPARATOR
Intervention: Control (non-aspirin users)
Number of subjects: 1423
Study: 38214256

Group type: EXPERIMENTAL
Intervention: Ridaforolimus-eluting stent with shortened dual antiplatelet therapy (DAPT) for 1 month for stable angina or 1 to 3 months for acute coronary syndrome at investigator's discretion.
Number of subjects: 315
Study: 38214257

Group type: EXPERIMENTAL
Intervention: Changes in LVFS (Left Ventricular Fractional Shortening)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Changes in LVEDD (Left Ventricular End-Diastolic Dimension)
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Changes in LV end-diastolic posterior wall thickness
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Changes in LV end-diastolic posterior wall thickness:LVEDD ratio
Number of subjects: 794

Group type: EXPERIMENTAL
Intervention: Mortality and transplantation outcomes
Number of subjects: 794
Study: 38214479

Group type: EXPERIMENTAL
Intervention: Repetitive Transcranial Magnetic Stimulation (rTMS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 38214539

Group type: EXPERIMENTAL
Intervention: Exercise and Nutrition Group (ENG)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 60
Study: 38214552

Group type: EXPERIMENTAL
Intervention: Oral TXA (2g) administered 2 hours before surgery and 4 hours after incision
Number of subjects: 228

Group type: COMPARATOR
Intervention: Intravenous TXA (1g) administered 30 minutes before surgery and 4 hours after incision
Number of subjects: 228

Group type: EXPERIMENTAL
Intervention: Oral TXA
Number of subjects: 228

Group type: COMPARATOR
Intervention: Oral TXA and Intravenous TXA
Number of subjects: 228
Study: 38214677

Group type: EXPERIMENTAL
Intervention: Coronary Sinus Reducer (CSR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo procedure
Number of subjects: 0
Study: 38214710

Group type: EXPERIMENTAL
Intervention: Shatavari (26,500 mg/d fresh weight)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Shatavari
Number of subjects: 12
Study: 38214733

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation (provided 50-500 ms after perturbation)
Number of subjects: 12

Group type: COMPARATOR
Intervention: No functional electrical stimulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Functional electrical stimulation
Number of subjects: 12
Study: 38214795

Group type: EXPERIMENTAL
Intervention: Cysticlean™ 240 mg
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study: 38214917

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38214956

Group type: EXPERIMENTAL
Intervention: Chanjo Kwa Wakati (community-based digital health intervention)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Delayed onset study arm (control group)
Number of subjects: 1200
Study: 38214963

Group type: EXPERIMENTAL
Intervention: Rosie chatbot treatment group
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control group (children's book)
Number of subjects: 29
Study: 38215127

Group type: EXPERIMENTAL
Intervention: Angiopuncture therapy
Number of subjects: 41
Study: 38215154

Group type: EXPERIMENTAL
Intervention: Caregiver coaching NDBI
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150
Study: 38215205

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring Device A
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring Device B
Number of subjects: 0
Study: 38215275

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 38215286

Group type: EXPERIMENTAL
Intervention: 200 μg selenium as selenium-enriched yeast
Number of subjects: 412

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 412
Study: 38215351

Group type: EXPERIMENTAL
Intervention: Lobar resection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sublobar resection
Number of subjects: 0
Study: 38215355

Group type: EXPERIMENTAL
Intervention: EV + P
Number of subjects: 149

Group type: COMPARATOR
Intervention: EV mono
Number of subjects: 149
Study: 38215395

Group type: COMPARATOR
Intervention: Bendamustine plus rituximab (BR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibrutinib
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibrutinib plus rituximab (IR)
Number of subjects: 0
Study: 38215438

Group type: EXPERIMENTAL
Intervention: recombinant polio:rhinovirus (lerapolturev)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: genetically modified oncolytic herpesvirus (G207)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: stereotactic catheter placement
Number of subjects: 19